Friday, April 4, 2025
9.5 C
London
HomeFinTechInteRNA Technologies: Extends Series B Financing Round Totaling €18.5M

InteRNA Technologies: Extends Series B Financing Round Totaling €18.5M

Date:

SMBC and Fujitsu Join Forces for AI-Powered Data Analytics Solutions

Exploring the Impact of Innovative Partnerships in the Financial...

Global Spending on Financial Market Data Reaches $44.3 Billion

Exploring the Factors Driving the Surge in Financial Data...

Visa Unveils Innovative AI Fraud-Fighting Tool

Revolutionizing Payment Security with Advanced TechnologyHighlights: Visa introduces a...
  • InteRNA Technologies, The Netherlands-based company that designs new therapies tackling cancer, closed an extended Series B financing round amounting to €18.5M in total
  • This Series B round led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures
  • Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round
  • The funding will enable the clinical evaluation of the company’s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors
  • Furthermore, the proceeds will used to develop and advance additional proprietary preclinical drug candidates adressing a variety of cancer indications thereby expanding InteRNA’s pipeline
  • The company’s microRNA lead candidate, INT-1B3, has a mechanism of action that addresses multiple hallmarks of cancer simultaneously

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories